GET THE APP

..

Journal of AIDS & Clinical Research

ISSN: 2155-6113

Open Access

Abstract

Milka A. Rodriguez*, Anthony Mills, Adam Stoker, Suqin Cai, Dusica Curanovic, Christos Petropoulos and Charles Walworth

Background: HIV-1 DNA drug resistance testing is increasingly used to guide antiretroviral (ARV) regimen switches in the setting of viral suppression. In this single-arm study, HIV-1 DNA resistance testing was used to assess eligibility for the fixed-dose combination of abacavir/ dolutegravir/lamivudine in the context of a switch study evaluating changes in bone mineral density in HIV-1 positive adults ages 50 years and older. Methods: Study subjects had viral loads which were <50 copies/mL at study screening. Susceptibility to each component of the switch regimen was assessed using an HIV-1 DNA genotypic resistance assay. A regimen switch was made only when the subject’s virus was sensitive to each component of the switch regimen. Viral load measurements were obtained per study protocol through weeks 24 and 48. Results: At week 24, the HIV-1 RNA viral load was <50 copies/mL for 44 of 44 study participants with available follow-up data, (95% CI [0.920, 1]). At week 48, 41 of 42 participants were virologically suppressed to <50 copies/mL, (95% CI [0.874, 0.999]); 1 participant had a viral load of 62 copies/mL. Conclusion: In this pre-selected population of virologically suppressed patients, HIV-1 DNA resistance testing successfully identified candidates for ARV treatment modification to an available single tablet regimen. These results support the utility of HIV-1 DNA drug resistance testing in the clinical setting.

HTML PDF

Share this article

Google Scholar citation report
Citations: 5061

Journal of AIDS & Clinical Research received 5061 citations as per Google Scholar report

Journal of AIDS & Clinical Research peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward